InflaRx’s lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase 3 clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease. It is in a Phase 2 trial for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease; a Phase 2a exploratory study to treat pyoderma gangraenosum, a chronic inflammatory skin disorder; and in Phase 2 for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma.
The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology and clinical trial collaboration and supply agreement with Merck.
Raymond James has an $8.12 price target. The consensus target is $5.50, and shares traded on Friday at $2.50. Hitting the Raymond James target would be a 232% gain.
Ocular Therapeutics
This micro-cap biopharmaceutical company could really be a big winner with an aging population. Ocular Therapeutics Inc. (NASDAQ: OCUL) focuses on the formulation, development and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology.
The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery. Its Dextenza is a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet ageelated macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant that is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease.
The company has a strategic collaboration with Regeneron Pharmaceuticals for the development and commercialization of products using the company’s sustainedelease hydrogel in combination with Regeneron’s large molecule VEGF-targeting compounds for the treatment of retinal diseases. It has a strategic collaboration with AffaMed Therapeutics for the development and commercialization of Dextenza and OTX-TIC. And it has a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry ageelated macular degeneration (dMAD).
The $14 Raymond James target price compares with a $13.29 consensus target. The stock traded on Friday at $3.00. A move to the target would be a 370% gain.
Sponsored: Tips for Investing
A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.
Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.
